From: Sex-specific differences and how to handle them in early psoriatic arthritis
Timepoint | Previous DMARD use | DMARD use | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Women | Men | ||||||||||
Methotrexate | Steroids | cs-DMARDs | b-DMARDs | no DMARD | Methotrexate | Steroids | Cs-DMARDs | b-DMARDs | None | ||
Baseline | 54% | 1% | 12% | 2% | 32% | 56% | 2% | 6% | 4% | 33% | |
T3 | Methotrexate | 77% | 1% | 6% | 6% | 10% | 88% | 4% | 1% | 7% | |
Steroids | 50% | 50% | 40% | 40% | 20% | ||||||
cs-DMARDs | 17% | 63% | 20% | 18% | 65% | 18% | |||||
b-DMARDs | 100% | 91% | 9% | ||||||||
None | 13% | 4% | 84% | 11% | 1% | 1% | 87% | ||||
T6 | Methotrexate | 88% | 5% | 3% | 4% | 82% | 1% | 2% | 6% | 9% | |
Steroids | 50% | 50% | 100% | ||||||||
cs-DMARDs | 13% | 81% | 6% | 5% | 79% | 5% | 11% | ||||
b-DMARDs | 13% | 73% | 13% | 7% | 79% | 14% | |||||
None | 10% | 5% | 3% | 81% | 9% | 1% | 1% | 1% | 87% | ||
T9 | Methotrexate | 69% | 12% | 6% | 13% | 78% | 5% | 6% | 12% | ||
Steroids | 100% | 25% | 25% | 25% | 25% | ||||||
cs-DMARDs | 11% | 78% | 11% | 72% | 11% | 17% | |||||
b-DMARDs | 22% | 72% | 6% | 5% | 79% | 16% | |||||
None | 7% | 2% | 5% | 87% | 4% | 3% | 93% | ||||
T12 | Methotrexate | 79% | 3% | 7% | 11% | 83% | 1% | 6% | 3% | 7% | |
Steroids | 100% | 100% | |||||||||
cs-DMARDs | 15% | 56% | 15% | 15% | 6% | 67% | 11% | 17% | |||
b-DMARDs | 5% | 86% | 10% | 4% | 85% | 12% | |||||
None | 13% | 6% | 1% | 80% | 12% | 1% | 5% | 1% | 80% |